tbuckley/cabot-search huggingface dataset:
Panic disorder and the menstrual cycle: panic disorder patients, healthy control subjects, and patients with premenstrual syndrome
Authors: M B Stein, P J Schmidt, D R Rubinow, T W Uhde
Journal: American Journal of Psychiatry (1989)

The authors prospectively evaluated 20 normally menstruating women with panic disorder across a minimum of two drug-free menstrual cycles. There were no significant effects of menstrual cycle phase on anxiety ratings in the panic disorder patients or in 20 healthy control subjects; this contrasted with a robust increase in premenstrual anxiety in 20 subjects with premenstrual syndrome. These findings suggest that the symptoms of panic disorder are not commonly exacerbated by the premenstrual phase of the menstrual cycle and highlight the need for prospective evaluation in the attempt to document an association between psychiatric symptoms and the menstrual cycle.
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Authors: Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock
Journal: Cancer Research (2016)

Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is to recruit patients who, while having failed previous treatments, may nevertheless respond to molecularly targeted drugs. We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profiling (CGP; next-generation sequencing, 236 genes). Of the 500 patients enrolled, 188 (37.6%) received either matched (N = 122/188, 65%) or unmatched therapy (N = 66/188, 35%). The most common reasons that patients were not evaluable for treatment included insufficient tissue, death, or hospice transfer. The median number of molecular alterations per patient was five (range, 1-14); median number of prior therapies, four. The most common diagnoses were ovarian cancer (18%), breast cancer (16%), sarcoma (13%), and renal cancer (7%). Of the 339 successfully profiled patients, 317 (93.5%) had at least one potentially actionable alteration. By calculating matching scores, based on the number of drug matches and genomic aberrations per patient, we found that high scores were independently associated with a greater frequency of stable disease ≥6 months/partial/complete remission [22% (high scores) vs. 9% (low scores), P = 0.024], longer time-to-treatment failure [hazard ratio (HR) = 0.52; 95% confidence interval (CI) = 0.36-0.74; P = 0.0003], and survival (HR = 0.65; 95% CI = 0.43-1.0; P = 0.05). Collectively, this study offers a clinical proof of concept for the utility of CGP in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented. Cancer Res; 76(13); 3690-701. ©2016 AACR.
A cluster of Legionnaires’ disease linked to an industrial plant in southeast Norway, June-July 2008
Authors: K Borgen, I Aaberge, Ø Werner-Johansen, K Gjøsund, B Størsrud, S Haugsten, K Nygård, T Krogh, E  A Høiby, D  A Caugant, A Kanestrøm, Ø Simonsen, H Blystad
Journal: Eurosurveillance (2008)

Binary file ES_Abstracts_Final_ECDC.txt matches
Abdominal Surgery
Authors: Claude E. Welch
Journal: New England Journal of Medicine (1971)

GallbladderSGOTThe serum glutamic oxalacetic transaminase (SGOT) is elevated particularly in patients with acute myocardial infarction or hepatitis. Adams et al.,177 investigating the elevation in 302 patients with gallbladder disease, found that 77 per cent of patients with acute, 70 per cent of those with subacute, and 10 per cent of those with chronic cholecystitis had elevated levels.Acute CholecystitisVan der Linden and Sunzel178 conducted a well controlled preoperative study to determine whether early operation (within 24 hours of admission) or delayed operation (two months later) was the better procedure. There were 70 patients in each group. The . . .
Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC)
Authors: A. Dowlati, R. Gray, D. H. Johnson, J. H. Schiller, J. Brahmer, A. B. Sandler
Journal: Journal of Clinical Oncology (2006)

7027 Background: E4599 was a phase II/III trial, in which 878 patients with advanced NSCLC were randomized to carboplatin + paclitaxel (PC arm) or PC + bevacizumab (PCB arm). Survival and progression free survival (PFS) were superior on the PCB arm (Sandler, ASCO 2005). The rationale for markers used in this correlative study were based on elevated vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble intercellular adhesion molecule-1 (ICAM) in NSCLC and changes in response to endothelial apoptosis. Methods: Prospective laboratory correlates included measurements of pretreatment plasma VEGF as well as pretreatment and week 7, bFGF, ICAM, and E-Selectin. 166 patients had pre- and 112 had post-treatment measurements. Measurements were made by ELISA. Low and high levels were defined as ≤ or &gt; than the median. Results: There were significant associations between E-Selectin and ICAM (p = .003) and between bFGF and VEGF (p = .01). E-Selectin (p = .01) and bFGF (p = .004) showed significant decreases from baseline at week 7 in both arms (Wilcoxon signed-rank tests). Only baseline ICAM showed a significant association with response. Patients with low baseline ICAM in both arms had a higher response rate of 29% vs 13% in high ICAM group (p=0.03, Fisher’s exact test). Patients with low baseline ICAM levels had a significantly better overall survival (p=0.00005) compared to patients with high ICAM levels as well as a better 1-year survival (65% vs 25%). No other factor predicted survival. Tests for treatment by factor interactions, which test whether the effect of treatment (the addition or not of bevacizumab) is different within the low and high levels were significant only for baseline ICAM where treatment interaction is significant for PFS (p=.04). This suggests a benefit from bevacizumab (53% reduction in the PFS hazard rate) in the group with low baseline ICAM levels vs no benefit from bevacizumab for patients with high levels. Conclusions: Baseline ICAM levels are strongly prognostic for survival and response to chemo. This exploratory correlative study suggests that improvements in PFS from the addition of bevacizumab occur mainly in patients with low baseline ICAM levels. [Table: see text]
High-dose methotrexate-induced neurotoxicity associated with elevation of CSF myelin basic protein.
Authors: E Neijstrom, D A Gabriel, R L Capizzi
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.4.593 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2580064 High-dose methotrexate-induced neurotoxicity associated with elevation of CSF myelin basic protein. E NeijstromxE NeijstromSearch for articles by this author , D A GabrielxD A GabrielSearch for articles by this author , R L CapizzixR L CapizziSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.4.593 PDF "High-dose methotrexate-induced neurotoxicity associated with elevation of CSF myelin basic protein.." Journal of Clinical Oncology, 3(4), pp. 593–594© 1985 by American Society of Clinical Oncology
Abstract B2-12: A systems biology approach for the discovery of differentiation therapeutics
Authors: Yulin Li, Jun Seita, Dean Felsher, David L. Dill
Journal: Cancer Research (2015)

Abstract Accurately assessing the changes in cellular differentiation status in response to drug treatments or genetic manipulations is crucial for understanding the tumorigenesis process and developing novel therapeutics for human cancer. Here we have developed a novel systems biology approach, called the Lineage Maturation Index (LMI), to define the changes in differentiation state of cancer cells based on their gene expression profiles. We have been focusing on hematopoietic malignancies, but this approach is applicable to many human cancer types. We define the expression profile of N genes within a cell to be a point in an N-dimensional space. A lineage vector is derived from a progenitor cell (such as a hematopoietic stem cell) to a mature cell (such as a granulocyte) based on the expression of these N genes. By projecting the expression profile of an unknown cell onto the lineage vector, an LMI can be computed for the differentiation state of this specific cell. Upon drug treatments or genetic manipulations, a shift in LMI from stem cells towards mature cell types indicates differentiation. We have confirmed that the LMI approach can track the differentiation of normal hematopoietic cells. We have further shown that differentiation is a major consequence of various targeted therapies against leukemia irrespective of the driving oncogenes. Most importantly, we have used this approach to analyze the Connectivity Map HL60 leukemia data set for drugs that can induce leukemia cells to differentiate. In addition to drugs known to have differentiation activities (such as all-trans retinoic acid and etoposide), we discovered that several novel drugs (such as dihydroergotamine, mebendazole, and clonidine) have potent differentiation activities in leukemia cells. Currently, we are expanding our study into multiple types of solid tumors, such as breast, prostate, and colon cancers. Our LMI approach is highly robust in characterizing differentiation of the cancer cells and discovering novel differentiation therapies for human cancer. Citation Format: Yulin Li, Jun Seita, Dean Felsher, David L. Dill. A systems biology approach for the discovery of differentiation therapeutics. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr B2-12.
In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates
Authors: K Geissler, P Valent, P Bettelheim, C Sillaber, B Wagner, P Kyrle, W Hinterberger, K Lechner, E Liehl, P Mayer
Journal: Blood (1992)
Lectures on the Relation of Sarcoma to Carcinoma
Authors: H. T. Butlin
Journal: BMJ (1880)

SARCOMA OF BONE. To the round-celled, spindle-celled, and mixed-celled groups, in which the subperiosteal tumours were arranged, must now be added a fourth group, to comprise the myeloid or giatit-celled sarcomata.In this group I shall include only those tumours which are so largely constituted of giant-cells that these cells produce a decided effect upon the appearance of the tumour-in other words, that they colour the tumour maroon or To [JulY 3, M8o.* Pathoogical Tratisactions, vol.xxii., page 2o6 (1870--LA YI.Ay VI 11111v IIlvllLLIb2 bIALCULl LllQnLnS, ana turee years atter operation-I TftE 2klrTISH MEDICAL YOURNAL.
Use of in Vitro Tests in Predlctlve Cancer Chemotherapy
Authors: Anne W. Hamburger
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article Use of in Vitro Tests in Predlctlve Cancer Chemotherapy Get access Anne W. Hamburger Anne W. Hamburger Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 66, Issue 6, June 1981, Pages 981–988, https://doi.org/10.1093/jnci/66.6.981 Published: 01 June 1981 Article history Received: 20 October 1980 Published: 01 June 1981
Outbreak of Salmonella Thompson in the Netherlands since July 2012
Authors: I H Friesema, A E de Jong, I A Fitz James, M E Heck, J H van den Kerkhof, D  W Notermans, W van Pelt, A Hofhuis
Journal: Eurosurveillance (2012)

Binary file ES_Abstracts_Final_ECDC.txt matches
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin
Authors: H. J. Lenz, R. J. Mayer, P. J. Gold, B. Mirtsching, P. J. Stella, A. L. Cohn, A. W. Pippas, N. Azarnia, M. N. Needle, E. Van Cutsem
Journal: Journal of Clinical Oncology (2004)

3510
Male and Female: A Reversion to Zoography
Authors: H T Ricketts
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NDM-1 producing Acinetobacter baumannii isolated from a patient repatriated to the Czech Republic from Egypt, July 2011
Authors: J Hrabák, M Štolbová, V Študentová, M Fridrichová, E Chudáčková, H Zemlickova
Journal: Eurosurveillance (2012)

We describe the isolation of an NDM-1-producing Acinetobacter baumannii in a Czech patient repatriated in July 2011 from Egypt. The infection spread to another patient on the same ward. Both isolates showed the same resistance pattern and were susceptible only to colistin. They had an identical PFGE pattern and belonged to the same sequence type ST 1. Sequencing of the blaNDM gene identified the NDM-1 variant of the carbapenemase, surrounded by two copies of insertion sequence ISAba125.
The SF-6D differentiates less in the lower ranges of the patient's utility when compared with the EQ-5D but has a better reliability and sensitivity to change
Authors: A Boonen, D Van Der Heijde, R Landewe, A Van Tubergen, Herman Mielants, M Dougados, S Van Der Linden
Journal: Annals of the Rheumatic Diseases (2005)
Not all mice are the same: Standardization of animal research data presentation
Authors: M. Bishr Omary, David E. Cohen, Emad M. El‐Omar, Rajiv Jalan, Malcolm J. Low, Michael H. Nathanson, Richard M. Peek, Jerrold R. Turner
Journal: Hepatology (2016)

Omary, M. Bishr; Cohen, David E.; El‐Omar, Emad M.; Jalan, Rajiv; Low, Malcolm J.; Nathanson, Michael H.; Peek, Richard M. Jr.; Turner, Jerrold R. Author Information
BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors.
Authors: C. Serrano, S. Simonetti, J. Hernandez, C. Valverde, J. Carles, S. Bague, R. Orellana, R. Somoza, S. Ramon y Cajal, C. Romagosa
Journal: Journal of Clinical Oncology (2010)

10043 Background: Benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumors are found to be either sporadic or related to neurofibromatosis (NF). Ras-Raf-MAPK pathway activation has already been described in both groups. While NF1 and NF2 loss of function leads to oncogenic Ras signaling in NF associated tumors, other mechanisms in the sporadic setting remain unknown. Somatic BRAF mutations are involved in the pathogenesis of a wide variety of cancers by triggering the Ras-Raf-MAPK pathway, which in turn constitutes a target for treatment with sorafenib. The aim of this study was to investigate the implication of BRAF V600E mutation in sporadic and NF-associated nerve sheath tumors. Methods: BRAF exon 15 PCR amplification and sequencing was done in 18 schwannomas (1 NF, 16 sporadic and 1 unknown), 16 neurofibromas (5 NF and 9 sporadic), and 19 MPNST (9 NF, 8 sporadic and 2 unknown). cDNA was obtained from formalin-fixed and paraffin-embedded tissue in all cases. Results: BRAF V600E mutations were identified only in nerve sheath tumors nonrelated to NF. Concretely, 3 of 16 sporadic schwannomas (18.7%) and in 1 of 8 sporadic MPNST (12.5%) showed BRAF mutation. Conclusions: Our findings confirm the presence of BRAF V600E mutations in sporadic schwannomas and MPNST but not in neurofibromas. These data suggest that BRAF V600E mutation might arise as a key event in cell growth and development of a subgroup of BPNST and MPNST nonrelated to NF. In addition, it also offers a strong rational to test sorafenib in further clinical trials in MPNST previously selected by the presence of BRAF mutations. Schwannoma (n=18) Neurofibroma (n=16) MPNST (n=19) NF 0/1 (0%) 0/5 (0%) 0/9 (0%) Sporadic 3/16 (18.7%) 0/11 (0%) 1/8 (12.5%) Unknown 0/1 (0%) 0/0 (0%) 0/2 (0%) No significant financial relationships to disclose.
Clouds and silver linings: positive experiences associated with primary affective disorders
Authors: K R Jamison, R H Gerner, C Hammen, C Padesky
Journal: American Journal of Psychiatry (1980)

Clinical psychiatry has focused almost entirely on the psychopathology of the affective disorders. The authors studied responses of 61 patients (35 bipolar. 26 unipolar) to questions about perceived short- and long-term benefits (increased sensitivity, sexuality, productivity, creativity, and social outgoingness) they attributed to their affective illness. Bipolar patients strongly indicated positive experiences associated with manic-depressive illness; few unipolar patients perceived their disorder in such a way. Significant sex differences emerged in the attributions made by bipolar patients.
“Corrupt” dietary guidelines must be rewritten to tackle obesity and diabetes, report warns
Authors: Ingrid Torjesen
Journal: BMJ (2016)

A “complete overhaul” of dietary advice is needed because current public health recommendations have been influenced by the food industry and are actually fuelling obesity and type 2 diabetes rather than reducing them, a hard hitting report has warned.1

The roots of obesity and type 2 diabetes are firmly embedded in diet—specifically, the “low fat” and “lower cholesterol” messages, said the report by the National Obesity Forum and the Public Health Collaboration.

It said that the flawed science behind those messages and dietary goals, subsequently “corrupted by commercial influences” of food companies, have resulted in increased consumption of low fat “junk” food, refined carbohydrates, and polyunsaturated vegetable oils.

“The conspicuous rise in obesity immediately following the introduction of these national guidelines suggests that they have been a root cause of the problem,” said the report, citing the …
Comparison Of Intensive Chemotherapy and Hypomethylating Agents Prior To Allogeneic Stem Cell Transplantation For Advanced MDS (RAEB, RAEB-T). A Study Of The MDS Subcommittee Of The Cmwp Of EBMT
Authors: Victoria T Potter, Simona Iacobelli, Anja van Biezen, Johann Maertens, Jean-Henri Bourhis, Jakob R. Passweg, I Yakhoub-Agha, Reza Tabrizi, Jacques-Olivier Bay, Marie Robin, Patrice Chevallier, Yves Chalandon, Anne Huynh, Theo de Witte, Nikolaus Kroeger
Journal: Blood (2013)
Abstract 21: Mutation profiling of patients with multiple primary cancers reveals some common genomic alterations in signaling pathways
Authors: Ruoyu Wang, Dewei Zhao, Zhiqiang Wang, Xuesong Gu, Shu Wen, Xuening Ji, Hong Cao, Bin Yang, Fei Wu, Jianguo Zhong, Nina Li, Shanshan Liang, Heming Li, Yuewei Zhang, Yan Ding
Journal: Clinical Cancer Research (2016)

Abstract Multiple primary cancers in a single individual are rare and usually challenging for effective treatments. Identification common cancer gene driver mutations and targets for patients with multiple primary malignant cancers will offer potential opportunities for effective personalized treatment. We have collected and analyzed tumor tissue samples from patients diagnosed with multiple primary cancers including lung cancer, kidney cancer, prostate cancer, and bone cancer from the Affiliated Zhongshan Hospital of Dalian University. Deep sequencing of the tumor samples was performed using TruSeq Amplicon - Cancer Panel (TSACP) which covers 48 cancer genes with more than 200 mutation hotspots. We have found that TP53 (75%), PIK3CA (50%), KDR(50%), VHL(50%), KRAS (25%), , FGFR(30%), EGFR(25%), HER2(25%) and ATM (25%) mutations are among the most common gene alterations across different types of primary cancers, they share some common cancer signaling pathways. Missense exon variation(4.13%) , non-coding exone variation(2.8%), and frameshift variation (0.41%) are among the most frequent alterations for functional effects. Targeted and chemotherapies have been recommended for personalized cancer treatments and circulating tumor cells (CTC) enumeration was conducted to monitor the prognosis of therapeutic efficacy. Citation Format: Ruoyu Wang, Dewei Zhao, Zhiqiang Wang, Xuesong Gu, Shu Wen, Xuening Ji, Hong Cao, Bin Yang, Fei Wu, Jianguo Zhong, Nina Li, Shanshan Liang, Heming Li, Yuewei Zhang, Yan Ding. Mutation profiling of patients with multiple primary cancers reveals some common genomic alterations in signaling pathways. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(1_Suppl):Abstract nr 21.